Janux Therapeutics Secures $35M Milestone Payment From BMY Deal
JANX earns $35M milestone payment from Bristol Myers as TRACTr-based cancer candidate advances, signaling progress in its tumor-activated therapy platform.
Zacks·2d ago
More News
OCGN Completes Early Enrollment in Pivotal Stargardt Disease Study
Ocugen completes GARDian3 enrollment early as OCU410ST gene therapy targets Stargardt disease with no approved treatments. Data readouts are expected in Q3.
Zacks·2d ago
Why ANI Pharmaceuticals (ANIP) is a Top Growth Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Zacks·2d ago
Kodiak Q4 Loss Wider Than Expected, Pipeline Development in Focus
KOD posts wider Q4 loss. However, its pipeline advances, with strong phase III data for Zenkuda driving accelerated regulatory plans.
Zacks·3d ago
AGIO Rises on Mitapivat Progress Toward Accelerated Approval in SCD
Agios Pharmaceuticals jumps 14% as it moves toward accelerated FDA approval for mitapivat in sickle cell disease after key regulatory feedback.
Zacks·3d ago
AZN Posts Data From Hypophosphatasia Program on Efzimfotase Alfa
AstraZeneca reports phase III data showing efzimfotase alfa improves bone health in children with HPP, with mixed adult results and an overall favorable safety profile.
Zacks·3d ago
Can ANI (ANIP) Climb 43.86% to Reach the Level Wall Street Analysts Expect?
The mean of analysts' price targets for ANI (ANIP) points to a 43.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Zacks·3d ago
ANIP Stock Outlook: Cortrophin Growth vs. Retina Reset
ANI Pharmaceuticals' growth pivots to Cortrophin Gel as retina headwinds weigh on 2025, with 2026 recovery hopes hinging on specialty momentum and portfolio reset.
Zacks·4d ago
Is ANIP Undervalued? How to Read Its 9.3x Forward P/E
ANI Pharmaceuticals trades at just 9.3x forward earnings, far below peers - raising a key question: is this a bargain or a signal of execution risks ahead?
Zacks·4d ago
ANI Pharmaceuticals 2026 Watchlist: Gout Sales Force and Rare Disease
ANIP eyes 2026 pivot as Rare Disease targets 60% of sales, with Cortrophin growth, gout sales force expansion, and retina rebound shaping momentum.